ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024
Low-Frequency Ultrasound Sensitive Piezo1 Channels Regulate Keloid-Related Characteristics of Fibroblasts.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 43 citations in OpenAlex.
- Mitochondria-targeted phototherapeutic system enabling spatiotemporal-controlled NADH depletion for keloid intervention.Materials today. Bio · 2026Article
- Sono-Mechanogenetics: Linking Ultrasound Physics With Cellular Mechanobiology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Focused ultrasound for cellular mechanoactivation and nanomedicine delivery in cancer.Biomedical microdevices · 2026Review
- Exploring the Complexities of TGF-β Signaling in Keloids: Beyond the Classical Smad Pathway.International journal of molecular sciences · 2026Review
- Radiation-Induced Salivary Gland Fibrosis: Mechanisms, Emerging Therapies, and Gelatin-Based Bioengineered Models.Gels (Basel, Switzerland) · 2026Review
- Cannabigerol (CBG) Modulates Neutrophil Activity and Ameliorates Rheumatoid Arthritis Pathogenesis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Targeting JAK/STAT signalling with cold atmospheric plasma: a potential therapy for systemic lupus erythematosus.Expert reviews in molecular medicine · 2026Review
- The therapeutic potential of Piezo1 channel-mediated ferroptosis and its inhibitor.Apoptosis : an international journal on programmed cell death · 2026Review
- Acidic tumor microenvironment-modulated nanoparticle potentiates gastric cancer photoimmunotherapy.Journal of advanced research · 2026Article
- Targeting Piezo1 can improve endometrial fibrosis by inhibiting ferroptosis in endothelial cells.iScience · 2026Article
- Ultrasound medicine in the era of precision theranostics: Mechanisms, molecular strategies, and clinical translation.Iranian journal of basic medical sciences · 2026Review
- Sonogenetics for precision medicine: from molecular toolkit to clinical translation.Theranostics · 2026Review
- Metabolic profiling of human melanoma cell lines with high and low metastatic capacity by 1H-NMR spectroscopy.PloS one · 2026Article
- Harnessing piezoelectricity for bone tissue engineering: recapitulating the electrophysiological microenvironment through smart biomaterials.Frontiers in bioengineering and biotechnology · 2026Review
- Reconstructing the Tumor Mechanical Microenvironment in Organoids: From Mechanical Cues to Biomimetic Modeling and Therapeutic Insights.International journal of medical sciences · 2026Review
- The Dual Role of Piezo1 in Cancer: Mechanotransduction, Microenvironment Remodelling, and Therapeutic Opportunities.Drug design, development and therapy · 2026Review
- A Nomogram Predicting Decreased Quality of Life in Patients with Keloids.Clinical, cosmetic and investigational dermatology · 2026Article
- Advances in the interplay between mechanical forces and inflammatory immunity in keloid formation.Frontiers in immunology · 2026Review
- The effect of melanocortin-4 receptor agonist drugs on obesity and metabolic risk factors: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2025Review
- Deciphering site-specific histopathological parameters with potential clinical value in head and neck squamous cell carcinomas.Oncology letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 2 countries.
Funding
Abstract
Keloids are benign fibroproliferative tumors that severely diminish the quality of life due to discomfort, dysfunction, and disfigurement. Recently, ultrasound technology as a noninvasive adjuvant therapy is developed to optimize treatment protocols. However, the biophysical mechanisms have not yet been fully elucidated. Here, it is proposed that piezo-type mechanosensitive ion channel component 1 (Piezo1) plays an important role in low-frequency sonophoresis (LFS) induced mechanical transduction pathways that trigger downstream cellular signaling processes. It is demonstrated that patient-derived primary keloid fibroblasts (PKF), NIH 3T3, and HFF-1 cell migration are inhibited, and PKF apoptosis is significantly increased by LFS stimulation. And the effects of LFS is diminished by the application of GsMTx-4, the selective inhibitor of Piezo1, and the knockdown of Piezo1. More importantly, the effects of LFS can be imitated by Yoda1, an agonist of Piezo1 channels. Establishing a patient-derived xenograft keloid implantation mouse model further verified these results, as LFS significantly decreased the volume and weight of the keloids. Moreover, blocking the Piezo1 channel impaired the effectiveness of LFS treatment. These results suggest that LFS inhibits the malignant characteristics of keloids by activating the Piezo1 channel, thus providing a theoretical basis for improving the clinical treatment of keloids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.